MedTrace Logo

TAS-102 in Treating Advanced Biliary Tract Cancers

NCT03278106 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Cholangiocarcinoma
  • Stage III Gallbladder Cancer AJCC v7
  • Stage IIIA Gallbladder Cancer AJCC v7
  • Stage IIIB Gallbladder Cancer AJCC v7
  • Stage IV Gallbladder Cancer AJCC v7
  • Stage IVA Gallbladder Cancer AJCC v7
  • Stage IVB Gallbladder Cancer AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Amit Mahipal · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2018-11-30
Completion
2021-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03278106 on ClinicalTrials.gov